Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ClearPoint Neuro, Inc. (CLPT)

ClearPoint Neuro Q3 revenue rises 36% to $12.1 million; net loss widens to $7.5 million

Mixed Impact 3 of 5 earnings Written later

ClearPoint Neuro reported third-quarter 2026 revenue of $12.1 million, up 36% from $8.9 million a year earlier, with growth led by the recently acquired IRRA flow products. The net loss widened to $7.5 million, or $0.24 per share, from $5.9 million, or $0.21 per share, as operating expenses rose 23% and gross margin fell to 58% from 63%. The company now estimates 2026 revenue of $48.0 million to $50.0 million.

Key points

  • Q3 2026 revenue was $12.1 million, up 36% from $8.9 million; neurosurgery navigation and therapy revenue rose 59% to $5.4 million.
  • Net loss was $7.5 million ($0.24 per share) versus $5.9 million ($0.21 per share) in Q3 2025; operating expenses rose to $13.4 million from $10.9 million.
  • Gross margin was 58% compared with 63%, which the company attributed to overhead at ClearPoint Advanced Laboratories and higher amortization of acquired intangible assets.
  • Cash and cash equivalents were $46.2 million at September 30, 2026, including $22.0 million in net proceeds from the at-the-market equity offering program.

The filing

CompanyClearPoint Neuro, Inc. (CLPT)
Form8-K, current report
Filed with the SECOct 28, 2026, 4:05 PM ET
Accession number0001193125-26-436125

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.